{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:46:33Z","timestamp":1789429593153,"version":"build-2803163510"},"reference-count":64,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Nintedanib is an anti-fibrotic medication endowed with a multi-kinase inhibitor profile and approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Nintedanib is believed to inhibit mainly Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), and Fibroblast Growth Factor (FGF) receptor kinases. The main objective was to identify potential tissue and\/or circulating biomarkers to demonstrate Nintedanib\u2019s target engagement and support its in vivo pharmacodynamic activity, consistent with its proposed mechanism(s) of action. In four independent experiments of bleomycin (BLM)-induced lung fibrosis model in rats, animals received Nintedanib (oral, 100 mg\/kg\/day) from day 7 post-BLM for 3 weeks. As expected, Nintedanib significantly reduced lung weight, the levels of lung fibrotic markers, and fibrotic areas. Moreover, Nintedanib-treated animals expressed lower levels of FGF2 in lung homogenates and higher plasma and lung levels of VEGF (\u22653-fold, p &lt; 0.05) compared to control animals. Lung proteomic analysis revealed the inhibition of receptor tyrosine kinases signaling in Nintedanib-treated animals. Circulating and lung levels of Nintedanib confirmed an optimal tissue distribution in the rat, consistent with the data reported for humans. Although VEGF ligand levels are elevated in the lungs of Nintedanib-treated animals, the VEGF signaling pathway remained functionally downregulated, strongly suggesting compensatory VEGF feedback delivery to its receptor blockade by Nintedanib. In summary, based on the present experimental findings in rats and supporting clinical preliminary evidence, increased VEGF levels can be reasonably considered an indicator of target engagement for Nintedanib and potentially for other VEGF modulators.<\/jats:p>","DOI":"10.3390\/ijms27010064","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:22:27Z","timestamp":1766578947000},"page":"64","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat Model"],"prefix":"10.3390","volume":"27","author":[{"given":"Vanessa","family":"Pitozzi","sequence":"first","affiliation":[{"name":"Chiesi Farmaceutici S.p.A., Global Research and Preclinical Development Area, Largo Belloli, 11\/A, 43122 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Lorenza","family":"Caruso","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici S.p.A., Global Research and Preclinical Development Area, Largo Belloli, 11\/A, 43122 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pontis","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici S.p.A., Global Research and Preclinical Development Area, Largo Belloli, 11\/A, 43122 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pioselli","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici S.p.A., Global Research and Preclinical Development Area, Largo Belloli, 11\/A, 43122 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ruscitti","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici S.p.A., Global Research and Preclinical Development Area, Largo Belloli, 11\/A, 43122 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4851-699X","authenticated-orcid":false,"given":"Maria Gloria","family":"Pittelli","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici S.p.A., Global Research and Preclinical Development Area, Largo Belloli, 11\/A, 43122 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0552-9205","authenticated-orcid":false,"given":"Costanza A. M.","family":"Lagrasta","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-4810","authenticated-orcid":false,"given":"Federico","family":"Quaini","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella Maria","family":"Nogara","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Aquino","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici S.p.A., Global Research and Preclinical Development Area, Largo Belloli, 11\/A, 43122 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Volta","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici S.p.A., Global Research and Preclinical Development Area, Largo Belloli, 11\/A, 43122 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Faietti","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici S.p.A., Global Research and Preclinical Development Area, Largo Belloli, 11\/A, 43122 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3183-6831","authenticated-orcid":false,"given":"Martina","family":"Bonatti","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Unit, Department of Medicine & Center for Molecular Medicine, Karolinska Institute, 17176 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1096-0596","authenticated-orcid":false,"given":"Paolo","family":"Spagnolo","sequence":"additional","affiliation":[{"name":"Respiratory Disease Unit, Department of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4384-6545","authenticated-orcid":false,"given":"Marcello","family":"Trevisani","sequence":"additional","affiliation":[{"name":"Chiesi Farmaceutici S.p.A., Global Research and Preclinical Development Area, Largo Belloli, 11\/A, 43122 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(25)00129-8","article-title":"Global Epidemiology and Burden of Interstitial Lung Disease","volume":"13","author":"Spagnolo","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2200957","DOI":"10.1183\/13993003.00957-2022","article-title":"Idiopathic Pulmonary Fibrosis: State of the Art for 2023","volume":"61","author":"Podolanczuk","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107798","DOI":"10.1016\/j.pharmthera.2020.107798","article-title":"Idiopathic Pulmonary Fibrosis: Disease Mechanisms and Drug Development","volume":"222","author":"Spagnolo","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/17476348.2014.915750","article-title":"Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis","volume":"8","author":"Poletti","year":"2014","journal-title":"Expert. Rev. Respir. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Spagnolo, P., Tzouvelekis, A., and Bonella, F. (2018). The Management of Patients With Idiopathic Pulmonary Fibrosis. Front. Med., 5.","DOI":"10.3389\/fmed.2018.00148"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An Official ATS\/ERS\/JRS\/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7150\/ijms.11579","article-title":"Role and New Insights of Pirfenidone in Fibrotic Diseases","volume":"12","year":"2015","journal-title":"Int. J. Med. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1165\/rcmb.2019-0328TR","article-title":"Pirfenidone: Molecular Mechanisms and Potential Clinical Applications in Lung Disease","volume":"62","author":"Ruwanpura","year":"2020","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"40523","DOI":"10.1038\/srep40523","article-title":"Pirfenidone Controls the Feedback Loop of the AT1R\/P38 MAPK\/Renin-Angiotensin System Axis by Regulating Liver X Receptor-\u03b1 in Myocardial Infarction-Induced Cardiac Fibrosis","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s10020-020-00173-3","article-title":"Pirfenidone Alleviates Pulmonary Fibrosis in Vitro and in Vivo through Regulating Wnt\/GSK-3\u03b2\/\u03b2-Catenin and TGF-\u03921\/Smad2\/3 Signaling Pathways","volume":"26","author":"Lv","year":"2020","journal-title":"Mol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jcmgh.2017.12.005","article-title":"Activation of Myofibroblast TRPA1 by Steroids and Pirfenidone Ameliorates Fibrosis in Experimental Crohn\u2019s Disease","volume":"5","author":"Kurahara","year":"2018","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"0345","DOI":"10.1358\/dot.2015.51.6.2336331","article-title":"Nintedanib in Idiopathic Pulmonary Fibrosis","volume":"51","author":"Woodcock","year":"2015","journal-title":"Drugs Today"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3867198","DOI":"10.1155\/2020\/3867198","article-title":"Effects of Nintedanib in an Animal Model of Liver Fibrosis","volume":"2020","author":"Wollin","year":"2020","journal-title":"BioMed Res. Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1042\/CS20170134","article-title":"Nintedanib, a Triple Tyrosine Kinase Inhibitor, Attenuates Renal Fibrosis in Chronic Kidney Disease","volume":"131","author":"Liu","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of Action of Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/CE.S82905","article-title":"Nintedanib: Evidence for Its Therapeutic Potential in Idiopathic Pulmonary Fibrosis","volume":"89","author":"Azuma","year":"2015","journal-title":"Core Evid."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"24235","DOI":"10.1038\/srep24235","article-title":"An Allosteric Cross-Talk Between the Activation Loop and the ATP Binding Site Regulates the Activation of Src Kinase","volume":"6","author":"Saladino","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40262-019-00766-0","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib","volume":"58","author":"Wind","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/jcph.752","article-title":"Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients with Advanced Cancer","volume":"56","author":"Dallinger","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10753-019-01101-2","article-title":"The Anti-Fibrotic and Anti-Inflammatory Potential of Bone Marrow\u2013Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats","volume":"43","author":"Gad","year":"2020","journal-title":"Inflammation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/s41401-021-00808-z","article-title":"Discovery of a Novel DDRs Kinase Inhibitor XBLJ-13 for the Treatment of Idiopathic Pulmonary Fibrosis","volume":"43","author":"Dong","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpb.2022.02.009","article-title":"Improvement of the Pharmacokinetics and Antifibrotic Effects of Nintedanib by Intrapulmonary Administration of a Nintedanib\u2013Hydroxypropyl-\u03b3-Cyclodextrin Inclusion Complex in Mice with Bleomycin-Induced Pulmonary Fibrosis","volume":"172","author":"Togami","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e001476","DOI":"10.1136\/bmjresp-2022-001476","article-title":"Time-course transcriptome analysis of a double challenge bleomycin-induced lung fibrosis rat model uncovers ECM homoeostasis-related translationally relevant genes","volume":"10","author":"Bonatti","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"ref_25","first-page":"1","article-title":"A novel mouse model of pulmonary fibrosis: Twice-repeated oropharyngeal bleomycin administration mimicking human pathology","volume":"103","author":"Wang","year":"2025","journal-title":"Biochem. Cell Biol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Bocchi, E., Pitozzi, V., Pontis, S., Caruso, P.L., Beghi, S., Caputi, M., and Trevisani, M. (2024). Ruscitti, Investigation of Aberrant Basaloid Cells in a Rat Model of Lung Fibrosis. Front. Biosci., 29.","DOI":"10.31083\/j.fbl2908305"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.bbamcr.2007.01.002","article-title":"Regulation of MAPKs by Growth Factors and Receptor Tyrosine Kinases","volume":"1773","author":"Katz","year":"2007","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1002\/jcb.30344","article-title":"Molecular Mechanism of VEGF and Its Role in Pathological Angiogenesis","volume":"123","author":"Ahmad","year":"2022","journal-title":"J. Cell. Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1378\/chest.11-1962","article-title":"Angiogenesis in Pulmonary Fibrosis","volume":"142","author":"Hanumegowda","year":"2012","journal-title":"Chest"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41232-021-00166-7","article-title":"VEGFR1-Tyrosine Kinase Signaling in Pulmonary Fibrosis","volume":"41","author":"Amano","year":"2021","journal-title":"Inflamm. Regen."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1172\/JCI10259","article-title":"Inhibition of VEGF Receptors Causes Lung Cell Apoptosis and Emphysema","volume":"106","author":"Kasahara","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1097\/01.CCM.0000281451.73202.F6","article-title":"Vascular Endothelial Growth Factor Promotes Physical Wound Repair and Is Anti-Apoptotic in Primary Distal Lung Epithelial and A549 Cells","volume":"35","author":"Roberts","year":"2007","journal-title":"Crit. Care Med."},{"key":"ref_34","unstructured":"Duffy, A.M., Bouchier-Hayes, D.J., and Harmey, J.H. (2013). Vascular Endothelial Growth Factor (VEGF) and Its Role in Non-Endothelial Cells: Autocrine Signalling by VEGF. Madame Curie Bioscience Database, Landes Bioscience."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e92192","DOI":"10.1172\/jci.insight.92192","article-title":"Antifibrotic Role of Vascular Endothelial Growth Factor in Pulmonary Fibrosis","volume":"2","author":"Murray","year":"2017","journal-title":"JCI Insight"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kotecha, J., Shulgina, L., Sexton, D., Atkins, C., and Wilson, A. (2016). Plasma Vascular Endothelial Growth Factor Concentration and Alveolar Nitric Oxide as Potential Predictors of Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis. J. Clin. Med., 5.","DOI":"10.3390\/jcm5090080"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Barratt, S.L., Flower, V.A., Pauling, J.D., and Millar, A.B. (2018). VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051269"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1164\/rccm.201603-0568OC","article-title":"Differential Expression of VEGF-A xxx Isoforms Is Critical for Development of Pulmonary Fibrosis","volume":"196","author":"Barratt","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00408-009-9223-x","article-title":"Significance of Serum Vascular Endothelial Growth Factor Level in Patients with Idiopathic Pulmonary Fibrosis","volume":"188","author":"Ando","year":"2010","journal-title":"Lung"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/thx.2003.009860","article-title":"Angiogenic Cytokines in Patients with Idiopathic Interstitial Pneumonia","volume":"59","author":"Simler","year":"2004","journal-title":"Thorax"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Malli, F., Koutsokera, A., Paraskeva, E., Zakynthinos, E., Papagianni, M., Makris, D., Tsilioni, I., Molyvdas, P.A., Gourgoulianis, K.I., and Daniil, Z. (2013). Endothelial Progenitor Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis: An Evolving Concept. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053658"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4049\/jimmunol.175.2.1224","article-title":"Anti-Vascular Endothelial Growth Factor Gene Therapy Attenuates Lung Injury and Fibrosis in Mice","volume":"175","author":"Hamada","year":"2005","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1073\/pnas.0912766107","article-title":"Loss of Myeloid Cell-Derived Vascular Endothelial Growth Factor Accelerates Fibrosis","volume":"107","author":"Stockmann","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1164\/rccm.2103112","article-title":"Decreased Level of Vascular Endothelial Growth Factor in Bronchoalveolar Lavage Fluid of Normal Smokers and Patients with Pulmonary Fibrosis","volume":"166","author":"Koyama","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zhong, B., and Luo, S. (2023). Identifying the Link between Serum VEGF and KL-6 Concentrations: A Correlation Analysis for Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Progression. Front. Med., 10, Correction in Front. Med. 2024, 11, 1424573, https:\/\/doi.org\/10.3389\/fmed.2024.1424573.","DOI":"10.3389\/fmed.2023.1282757"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.2147\/DDDT.S415453","article-title":"Inhibition of LPA-LPAR1 and VEGF-VEGFR2 Signaling in IPF Treatment","volume":"17","author":"Luo","year":"2023","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"L990","DOI":"10.1152\/ajplung.00436.2020","article-title":"VEGF\/Src Signaling Mediated Pleural Barrier Damage and Increased Permeability Contributes to Subpleural Pulmonary Fibrosis","volume":"320","author":"Lu","year":"2021","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Biener, L., Kruse, J., Tuleta, I., Pizarro, C., Kreuter, M., Birring, S.S., Nickenig, G., and Skowasch, D. (2021). Association of Proangiogenic and Profibrotic Serum Markers with Lung Function and Quality of Life in Sarcoidosis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247197"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"eaba1983","DOI":"10.1126\/sciadv.aba1983","article-title":"Single-Cell RNA-Seq Reveals Ectopic and Aberrant Lung-Resident Cell Populations in Idiopathic Pulmonary Fibrosis","volume":"6","author":"Adams","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"eaba1972","DOI":"10.1126\/sciadv.aba1972","article-title":"Single-Cell RNA Sequencing Reveals Profibrotic Roles of Distinct Epithelial and Mesenchymal Lineages in Pulmonary Fibrosis","volume":"6","author":"Habermann","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-5-32","article-title":"Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins","volume":"5","author":"DePrimo","year":"2007","journal-title":"J. Transl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1158\/1078-0432.CCR-11-1677","article-title":"Pharmacodynamic Study Using FLT PET\/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate Free","volume":"17","author":"Liu","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdi118","article-title":"Soluble markers for the assessment of biological activity with PTK787\/ZK 222584 (PTK\/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials","volume":"16","author":"Drevs","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"H153","DOI":"10.1152\/ajpheart.00254.2003","article-title":"Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells","volume":"286","author":"Popel","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_56","unstructured":"Bonatti, M., Pitozzi, V., Caruso, P., Pontis, S., Pittelli, M.G., Frati, C., Madeddu, D., Quaini, F., Lagrasta, C.A.M., and Minato, I. (2026). Transcriptomic analysis reveals lipid metabolism and macrophage involvement associated with nintedanib treatment in a rat bleomycin model. Br. J. Pharmacol, in press."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Wang, Y., Yang, C., Gu, Q., Sims, M., Gu, W., Pfeffer, L.M., and Yue, J. (2015). KLF4 Promotes Angiogenesis by Activating VEGF Signaling in Human Retinal Microvascular Endothelial Cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130341"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/s41467-019-09050-y","article-title":"Etv6 activates vegfa expression through positive and negative transcriptional regulatory networks in Xenopus embryos","volume":"10","author":"Li","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_59","first-page":"781","article-title":"Anti-Fibrotic Effect and In Vivo Target Engagement of Nintedanib Administered by Oral Gavage or by a Medicated Diet in a Bleomycin Lung Fibrosis Model in the Rat","volume":"60","author":"Trevisani","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_60","unstructured":"Clark, J.D., Gebhart, G.F., Gonder, J.C., Keeling, M.E., and Kohn, D.F. (1996). Guide for the Care and Use of Laboratory Animals, National Academy Press. [7th ed]."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jcp.41.4.467","article-title":"Simple Method of Estimating. Severity of Pulmonary Fibrosis on a Numerical Scale","volume":"41","author":"Ashcroft","year":"1988","journal-title":"J. Clin. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2144\/000112729","article-title":"Standardized Quantification of Pulmonary Fibrosis in Histological Samples","volume":"44","author":"Gitter","year":"2008","journal-title":"Biotechniques"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"L376","DOI":"10.1152\/ajplung.00311.2019","article-title":"Modeling Pulmonary Fibrosis through Bleomycin Delivered by Osmotic Minipump: A New Histomorphometric Method of Evaluation","volume":"318","author":"Ravanetti","year":"2020","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41596-018-0014-9","article-title":"High-Throughput and High-Sensitivity Phosphoproteomics with the EasyPhos Platform","volume":"13","author":"Humphrey","year":"2018","journal-title":"Nat. Protoc."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/1\/64\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:24:53Z","timestamp":1766579093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/1\/64"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ijms27010064"],"URL":"https:\/\/doi.org\/10.3390\/ijms27010064","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]}}}